<DOC>
	<DOCNO>NCT03020472</DOCNO>
	<brief_summary>This pilot study investigate B-cell response follow vaccination live , attenuated influenza vaccine ( LAIV ) healthy child 2 year age blood sample take designated time point vaccination .</brief_summary>
	<brief_title>Kinetics B-Cell Responses Live , Attenuated Influenza Vaccine ( LAIV ) Young Children Two Years Age</brief_title>
	<detailed_description>This exploratory study determine peripheral antibody secrete cell response Days 5-13 immunization live , attenuate influenza vaccine ( LAIV ) . Investigators hop enroll 27 healthy child , 2 year age prior LAIV trivalent inactivate vaccine ( TIV ) within past 2 year . Due low enrollment , study halt . Due limit number sample , analysis perform .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria 1 . Otherwise healthy child , age 2435 month age , inclusive . 2 . Parent ( ) guardian ( ) willing sign inform consent . 3 . Availability followup plan duration study . 4 . Acceptable medical history screen evaluation brief clinical assessment . 5 . Able understand comply plan study procedure Exclusion Criteria 1 . Prior vaccination LAIV . 2 . TIV vaccination two prior influenza vaccine season 3 . Known prior MD diagnosis , hospitalization influenza 4 . History asthma , active/recurrent wheeze reactive airway disease 5 . History immunodeficiency 6 . Known suspected impairment immunologic function include , limited , clinically significant liver disease ; diabetes mellitus ; moderate severe kidney impairment . 7 . Known underlying medical condition ( e.g . hemoglobinopathy , congestive heart failure ) predisposing influenza complication . 8 . Household contact immunodeficiency due disease , medication radiation 9 . Child receive aspirin therapy aspirincontaining therapy 10 . History GuillainBarr√© syndrome 11 . Malignancy , squamous cell basal cell skin cancer 12 . Autoimmune disease 13 . Use immunosuppressive medication . Corticosteroid nasal spray permissible . 14 . Use antiviral agent Influenza A and/or B ( Tamiflu , Relenza , Flumodine , Symmetrel ) less 48 hour and/or less two week administration FluMist . 15 . History blood dyscrasia , renal disease , hemoglobinopathies require regular medical followup hospitalization precede year . 16 . Use investigational agent within 30 day prior study 17 . Receipt blood product immunoglobulin past 6 month 18 . Donation equivalent unit blood within 6 week prior enrollment 19 . Acute febrile illness day vaccination 20 . Known allergy component vaccine , include egg egg product , gentamicin , gelatin , arginine , know lifethreatening reaction previous influenza vaccination . 21 . Concurrent participation investigational protocol receipt investigational product within previous 30 day plan receipt investigational product within 28 day follow last immunization dose . 22 . Any condition , opinion investigator , might interfere study objective</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Live , attenuate influenza vaccine</keyword>
	<keyword>Children</keyword>
</DOC>